Westwood-based biotechnology analysis firm Dalton Bioanalytics was certainly one of 14 life-sciences firms — and the one one from Los Angeles — to take part within the BioTools Innovator Accelerator program.
Based in 2019, Dalton says it’s constructing the subsequent era of blood evaluation utilizing its expertise to digitize the biochemical composition of plasma and different tissues, quantifying 1000’s of molecules in a single-shot assay.
Historically, multiomics, information units of various measurements mixed, requires the collaboration of a number of laboratories, a extra expensive and sophisticated course of.
Dalton, nevertheless, analyzes proteins, lipids, and metabolites in a single process.
Solely 26 firms have been chosen from the 160 candidates from 23 international locations for the BioTools Innovator Accelerator program. Greater than 30 business judges from life science companies selected the 14 firms chosen for that cohort. 5 of the businesses might be chosen to compete for the 2022 BioTools Innovator title and a $250,000 grand prize in the course of the BioTools Innovator Capstone Occasion, which is able to happen in October in Carlsbad, California.
This system is facilitated by Westwood-based BioTools Innovator, which was developed by the workforce behind accelerator MedTech Innovator. Its objective is to advance life science-tools innovation and enhance human well being by supporting startups creating biotechnology merchandise with mentorship, funding and networking alternatives.
“We launched BioTools Innovator to fill a niche within the life science business the place promising applied sciences falter as a consequence of lack of subtle steerage that stops entrepreneurs from making avoidable errors,” Kathryn Zavala, managing director of BioTools Innovator, stated in a press release. “These 14 firms symbolize the subsequent frontier of revolutionary applied sciences that may assist us develop options to diagnose and deal with ailments extra successfully and dwell more healthy. We’re thrilled to welcome them to the cohort.”